The Government of Canada has announced its intention to merge BDC and EDC. Today, BDC remains BDC, and we remain fully committed to Canadian entrepreneurs. Learn more

The Government of Canada has announced its intention to merge BDC and EDC. Today, BDC remains BDC, and we remain fully committed to Canadian entrepreneurs. Learn more
FR
Search
Search
Clementia Pharmaceuticals logo
Exited company

Clementia Pharmaceuticals

Details
Region
Quebec
Industry sector
Drugs
Investment year
2012
Fund
Healthcare Venture Fund
Our partnership

Clementia is a BDC Capital Healthcare Venture Fund company, co-managed in partnership by Amplitude Venture Capital.

Contact

Jean-François Pariseau, Founding Partner at Amplitude Venture Capital

About the company

Clementia is a developing Retinoic acid receptor gamma agonists (RARγ) to address diseases of heterotopic ossification, including Fibrodysplasia Ossificans Progressiva. The company was acquired by Ipsen in 2019.